To explore whether compound DBH2 could be one of the potential partner with imatinib for CML treatment, using SCL-tTA-BCR/ABL transgenic model mice as donor and lethally irradiated wild type mice as receiver, bone marrow transplantation (BMT) was performed for establishing the BCR/ABL model mice in this study (Fig. 3A). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.